Stocks
ACADIA Pharmaceuticals Inc.ACAD
NASDAQHealthcareBiotechnology$20.61-3.10%
Focused on central nervous system disorders, this biopharmaceutical firm develops and commercializes innovative therapies for unmet medical needs. Its lead product targets Parkinson's disease psychosis and schizophrenia, making it a key player in neuropsychiatric treatments. Investors monitor ACAD for pipeline progress and commercialization execution in this high-specialization market.
Market Cap: $3.5B52W Range: $13.40 – $28.35
Congressional Interest in ACADIA Pharmaceuticals Inc. (ACAD)
2 members of Congress have disclosed 3 trades in ACADIA Pharmaceuticals Inc. (ACAD), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
2
Buys
0
Sells
3
Who in Congress Is Trading ACAD?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-06-16 | Christopher L. Jacobs | sell | $1K – $15K |
| 2020-09-08 | Christopher L. Jacobs | sell | $1K – $15K |